Gene

Announcing Andrew A. Wilson MD as the Alpha-1 Foundation's new Scientific Director

Retrieved on: 
Friday, December 2, 2022

CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.

Key Points: 
  • CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.
  • Dr. Wilson assumes this role with a long-standing passion and commitment to the Alpha-1 community.
  • "I am honored and humbled to have been selected as the new Scientific Director of the Alpha-1 Foundation.
  • I hope that as Scientific Director I will be able to help the Foundation to advance its mission and work towards a cure for AATD."

Fortero Launches Online Diagnostics Service Specializing in Thinning Hair Treatments

Retrieved on: 
Friday, December 2, 2022

LOS ANGELES, Dec. 2, 2022 /PRNewswire-PRWeb/ -- On November 1, 2022, SEISEIDOU AMERICA, INC. began an online diagnosis service for hair loss treatments in the United States.

Key Points: 
  • On November 1, 2022, SEISEIDOU AMERICA, INC. began an online diagnosis service for hair loss treatments in the United States.
  • LOS ANGELES, Dec. 2, 2022 /PRNewswire-PRWeb/ -- On November 1, 2022, SEISEIDOU AMERICA, INC. began an online diagnosis service for hair loss treatments in the United States.
  • Fortero wants all men suffering from thinning hair to regain their vitality and confidence!
  • Regardless of age, lifestyle, or degree of hair loss, this product offers the most efficient and approved formula to beat genes and improve thinning hair.

RNA Sequencing Services Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.

Key Points: 
  • The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.
  • Currently, more than 70 companies offer services related to RNA sequencing.
  • A general overview of RNA sequencing, along with information on the key steps involved in the process, details on the various types, methods and applications of RNA sequencing, as well as the advantages and limitations associated with RNA sequencing.
  • Which type of next generation sequencing kits are being used to collect samples for RNA sequencing?

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI

Retrieved on: 
Thursday, December 1, 2022

The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .

Key Points: 
  • The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .
  • With the most significantly perturbed genes serving as biomarkers, researchers performed survival analysis across 33 cancer types and selected those that showed high confidence stratification among cancer patients.
  • Insilico Medicines AI-driven PandaOmics platform was used to perform a comprehensive differential gene expression analysis, survival stratification, and target discovery.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Retrieved on: 
Thursday, December 1, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
  • Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
  • Over 80% of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Commercial Dishwashers Destroy Protective Layer in Gut

Retrieved on: 
Thursday, December 1, 2022

ZURICH, Dec. 1, 2022 /PRNewswire/ -- Whether it's at a restaurant, at school or in the barracks, commercial dishwashers help plates, glasses and cutlery become squeaky clean and dry in a matter of minutes. These practical appliances come with risks, however, as was recently discovered in a new study by researchers at the Swiss Institute of Allergy and Asthma Research (SIAF), an associated institute of the University of Zurich (UZH). One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.

Key Points: 
  • This damages the natural protective layer in the gut and can contribute to the onset of chronic diseases, as demonstrated by researchers working with organoids at the Swiss Institute of Allergy and Asthma Research, an associated UZH institute.
  • One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.
  • A typical cycle in a commercial dishwasher involves circulating hot water and detergent for around 60 seconds at high pressure.
  • Akdis calls for an immediate response: "It is important to inform the public about this risk, since alcohol ethoxylates seem to be commonly used in commercial dishwashers."

Commercial Dishwashers Destroy Protective Layer in Gut

Retrieved on: 
Thursday, December 1, 2022

ZURICH, Dec. 1, 2022 /PRNewswire/ -- Whether it's at a restaurant, at school or in the barracks, commercial dishwashers help plates, glasses and cutlery become squeaky clean and dry in a matter of minutes. These practical appliances come with risks, however, as was recently discovered in a new study by researchers at the Swiss Institute of Allergy and Asthma Research (SIAF), an associated institute of the University of Zurich (UZH). One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.

Key Points: 
  • This damages the natural protective layer in the gut and can contribute to the onset of chronic diseases, as demonstrated by researchers working with organoids at the Swiss Institute of Allergy and Asthma Research, an associated UZH institute.
  • One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.
  • A typical cycle in a commercial dishwasher involves circulating hot water and detergent for around 60 seconds at high pressure.
  • Akdis calls for an immediate response: "It is important to inform the public about this risk, since alcohol ethoxylates seem to be commonly used in commercial dishwashers."

Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market

Retrieved on: 
Thursday, December 1, 2022

MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening. Asuragen will leverage its gold-standard PCR technology with Oxford Nanopore's any-read-length DNA sequencing capabilities to develop the first sequencing system to identify the most challenging yet high prevalence carrier genes in a single, unified workstream that today requires multiple other methods.

Key Points: 
  • MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen,a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.
  • Carrier screening identifies at-risk-couples (ARCs) with pathogenic variants associated with severe genetic disorders.
  • This information can be used to determine the residual risk for passing on a condition to their children and help guide reproductive decision-making.
  • "We are really pleased to be working with Asuragen to develop more robust, reliable and accessible options for reproductive health and carrier screening," said Gordon Sanghera, Chief Executive Officer of Oxford Nanopore Technologies.